TP53 and acute myeloid leukemia: A phase Ib/II study is ongoing to evaluate the safety and efficacy of APR-246 in combination with azacitidine for TP53-mutated myeloid neoplasms, including oligoblastic AML (20–30% myeloblasts) (NCT03072043).